Search research articles
Contact Us
Filters
Showing results (1-10 of 92) with videos related to
Page
of 10
Sort By:
Cancer Treatment Reviews
|
December 20, 2005
What is the best schedule for administration of gemcitabine-taxane?
R Colomer
Medicina Clinica
|
July 3, 1998
[Treatment of lymphoma in the aged]
H Gómez, R Colomer
Cancer
|
October 15, 1989
Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease
R Colomer, A Ruibal, L Salvador
British Journal of Cancer
|
December 16, 2004
Management of metastatic breast cancer: are we prepared to cope with our own success?
A Jimeno, H Cortés-Funes, R Colomer
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|
May 20, 2005
Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells
J A Menendez, R Lupu, R Colomer
British Journal of Cancer
|
February 1, 1989
Circulating CA 15-3 antigen levels in non-mammary malignancies
R Colomer, A Ruibal, J Genollà, et al.
Cancer Treatment Reports
|
May 1, 1987
Meningioma preceding breast cancer
R Colomer, L Jolis, R Hidalgo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 1999
Correspondence re: S. Shimoyama et al., increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin. Cancer Res., 5: 1125-1130, 1999
S Montero, B Lloveras, H Cortés-Funes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2005
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification
J A Menendez, L Vellon, R Colomer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 1998
Angiogenin expression and prognosis in primary breast carcinoma
S Montero, C Guzmán, H Cortés-Funes, et al.
Page
of 10
Search research articles
Search
Showing results (1-10 of 92) with videos related to
Sort By:
Page
of 10
Cancer Treatment Reviews
|
December 20, 2005
What is the best schedule for administration of gemcitabine-taxane?
R Colomer
Medicina Clinica
|
July 3, 1998
[Treatment of lymphoma in the aged]
H Gómez, R Colomer
Cancer
|
October 15, 1989
Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease
R Colomer, A Ruibal, L Salvador
British Journal of Cancer
|
December 16, 2004
Management of metastatic breast cancer: are we prepared to cope with our own success?
A Jimeno, H Cortés-Funes, R Colomer
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|
May 20, 2005
Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells
J A Menendez, R Lupu, R Colomer
British Journal of Cancer
|
February 1, 1989
Circulating CA 15-3 antigen levels in non-mammary malignancies
R Colomer, A Ruibal, J Genollà, et al.
Cancer Treatment Reports
|
May 1, 1987
Meningioma preceding breast cancer
R Colomer, L Jolis, R Hidalgo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 10, 1999
Correspondence re: S. Shimoyama et al., increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin. Cancer Res., 5: 1125-1130, 1999
S Montero, B Lloveras, H Cortés-Funes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 12, 2005
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification
J A Menendez, L Vellon, R Colomer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 1998
Angiogenin expression and prognosis in primary breast carcinoma
S Montero, C Guzmán, H Cortés-Funes, et al.
Page
of 10